{
  "id": 13962757,
  "title": "Pharma’s $500B patent problem will come in waves — not as a cliff",
  "url": "https://urgent.news/2026/10/12/pharmas-500b-patent-problem-will-come-in-waves-not-as-a-cliff",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-12T13:16:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/pharma-patent-cliff-merck-abbvie-dealmaking/832700/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}